Get the Stockscreener App
0.8899
2.05%
-0.0123
Pds Biotechnology Corporation stock is traded at $0.8899, with a volume of 427.58K.
It is down -2.05% in the last 24 hours and down -2.27% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$0.9022
Open:
$0.89
24h Volume:
427.58K
Relative Volume:
0.51
Market Cap:
$48.70M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.7606
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-6.59%
1M Performance:
-2.27%
6M Performance:
-25.11%
1Y Performance:
-39.06%
1-Day Range:
$0.855
$0.8967
1-Week Range:
$0.855
$1.01
52-Week Range:
$0.703
$2.20
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.8899 | 49.37M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.70 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.46 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.94 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.80 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.76 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com Nigeria
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
PDS Biotech secures patent for cancer immunotherapy PDS0101 - Investing.com
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - The Manila Times
New PDS0101 patent extends U.S. market protection toward 20 years - Stock Titan
Aug Macro: Can PDS Biotechnology Corporation stock outperform in a bear market2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Miss: Can STRW maintain sales growthMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Growth Value: Is PDS Biotechnology Corporation trading at a discount - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path By Investing.com - Investing.com South Africa
PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Nigeria
PDS Biotech Announces FDA Alignment on Use of Progression Free Survival as Primary Endpoint - marketscreener.com
PDS Biotech submits amended protocol for phase 3 cancer trial By Investing.com - Investing.com India
PDS Biotech Files Amended Protocol for Phase 3 VERSATILE-003 Trial to Seek Accelerated Approval of PDS0101 - Quiver Quantitative
Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan
How institutional buying supports PDS Biotechnology Corporation stockJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - Улправда
Is PDS Biotechnology Corporation stock resilient to inflation2025 Earnings Impact & AI Forecasted Entry/Exit Points - ulpravda.ru
Does PDS Biotechnology Corporation stock trade at a discount to peersM&A Rumor & Verified Short-Term Trading Plans - Улправда
PDS Biotechnology (NASDAQ:PDSB) Trading 5% Higher – Here’s Why - Defense World
Aug Sentiment: How PDS Biotechnology Corporation stock trades during market volatility2025 Pullback Review & Entry and Exit Point Strategies - Улправда
How interest rate cuts could boost PDS Biotechnology Corporation stockSell Signal & Reliable Entry Point Alerts - Улправда
Guidance Update: Does PDS Biotechnology Corporation stock trade at a discount to peersMarket Volume Report & Verified Momentum Watchlists - Улправда
Can PDS Biotechnology Corporation stock sustain institutional interest2025 Pullback Review & Weekly Chart Analysis and Trade Guides - DonanımHaber
Will PDS Biotechnology Corporation stock continue upward momentum2025 Institutional Moves & Daily Market Momentum Tracking - bolumsonucanavari.com
How PDS Biotechnology Corporation stock performs after earningsJuly 2025 Update & Capital Efficiency Focused Ideas - DonanımHaber
Aug Spikes: How supply chain issues affect PDS Biotechnology Corporation stockWeekly Market Outlook & Real-Time Volume Trigger Notifications - moha.gov.vn
PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened - Defense World
Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers - setenews.com
PDS Biotech secures new patent for cancer immunotherapy in Japan By Investing.com - Investing.com Australia
PDS Biotechnology Secures New Patent for PDS0101 - TipRanks
PDS Biotech secures new patent for cancer immunotherapy in Japan - Investing.com
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - The Manila Times
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - sharewise.com
EPS Watch: How interest rate cuts could boost PDS Biotechnology Corporation stockTrade Risk Report & Precise Buy Zone Tips - moha.gov.vn
How supply chain issues affect PDS Biotechnology Corporation stock2025 Macro Impact & AI Powered Market Trend Analysis - Newser
A better buy-in window may exist right now for PDS Biotechnology Corporation (PDSB) - setenews.com
Is PDS Biotechnology Corporation stock ready for breakoutOptions Play & Real-Time Volume Spike Alerts - Newser
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech announces scheduling of Type C meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - moha.gov.vn
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pds Biotechnology Corporation Stock (PDSB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Glover Stephen C. | Director |
Feb 28 '25 |
Buy |
1.66 |
15,061 |
25,001 |
78,851 |
2.27%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):